Cannassure Therapeutics Past Earnings Performance
Past criteria checks 0/6
Cannassure Therapeutics has been growing earnings at an average annual rate of 31.5%, while the Pharmaceuticals industry saw earnings growing at 11.3% annually. Revenues have been growing at an average rate of 48.2% per year.
Key information
31.5%
Earnings growth rate
46.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 35.1% |
| Revenue growth rate | 48.2% |
| Return on equity | n/a |
| Net Margin | -16.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Cannassure Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 11 | -2 | 1 | 1 |
| 30 Sep 23 | 19 | -2 | 2 | 1 |
| 30 Jun 23 | 27 | -2 | 3 | 1 |
| 31 Mar 23 | 31 | -4 | 3 | 2 |
| 31 Dec 22 | 34 | -5 | 4 | 2 |
| 30 Sep 22 | 36 | -8 | 4 | 3 |
| 30 Jun 22 | 38 | -10 | 5 | 4 |
| 31 Mar 22 | 36 | -13 | 6 | 3 |
| 31 Dec 21 | 34 | -17 | 7 | 2 |
| 30 Sep 21 | 25 | -21 | 7 | 2 |
| 30 Jun 21 | 16 | -25 | 7 | 1 |
| 31 Mar 21 | 10 | -27 | 7 | 4 |
| 31 Dec 20 | 3 | -29 | 7 | 6 |
| 30 Sep 20 | 2 | -26 | 7 | 9 |
| 30 Jun 20 | 0 | -23 | 7 | 12 |
| 31 Mar 20 | 0 | -20 | 7 | 10 |
| 31 Dec 19 | 0 | -17 | 7 | 9 |
| 30 Sep 19 | 0 | -26 | 9 | 6 |
| 30 Jun 19 | 0 | -25 | 11 | 4 |
| 31 Mar 19 | 0 | -25 | 12 | 3 |
| 31 Dec 18 | 0 | -24 | 13 | 1 |
| 30 Sep 18 | 0 | -11 | 10 | 1 |
| 30 Jun 18 | 0 | -6 | 6 | 0 |
| 31 Mar 18 | 0 | -4 | 3 | 0 |
Quality Earnings: CSURE-M is currently unprofitable.
Growing Profit Margin: CSURE-M is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CSURE-M is unprofitable, but has reduced losses over the past 5 years at a rate of 31.5% per year.
Accelerating Growth: Unable to compare CSURE-M's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CSURE-M is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6%).
Return on Equity
High ROE: CSURE-M's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.